FDA-cleared profile

CINA

AVICENNA.AI · CT/CTA · FDA-cleared (510(k))

Authorized purpose: CINA analyzes nonenhanced head CT for suspected intracranial hemorrhage and head CTA for suspected large-vessel occlusion for computer-aided triage and notification in parallel with standard care; the output is not a primary diagnosis.

Clinical role
CT image networking, processing, enhancement, triage, measurement, or professional workflow support.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Input protocol, contrast, anatomy, model, software version, output review, and local integration limits are release-specific. CINA analyzes nonenhanced head CT for suspected intracranial hemorrhage and head CTA for suspected large-vessel occlusion for computer-aided triage and notification in parallel with standard care; the output is not a primary diagnosis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: CINA analyzes nonenhanced head CT for suspected intracranial hemorrhage and head CTA for suspected large-vessel occlusion for computer-aided triage and notification in parallel with standard care; the output is not a primary diagnosis.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Supported CT or CTA DICOM images and the metadata required by the exact release-specific processing workflow.
  • Who uses it?Intended users: Qualified radiologists and other trained imaging professionals.
  • What does the software produce?Output: Processed CT image objects, measurements, notifications, or worklist outputs for professional review.
  • What is its most important limitation?Key limitation: Input protocol, contrast, anatomy, model, software version, output review, and local integration limits are release-specific. CINA analyzes nonenhanced head CT for suspected intracranial hemorrhage and head CTA for suspected large-vessel occlusion for computer-aided triage and notification in parallel with standard care; the output is not a primary diagnosis.

Clinical takeaway. Clinical role: CINA analyzes nonenhanced head CT for suspected intracranial hemorrhage and head CTA for suspected large-vessel occlusion for computer-aided triage and notification in parallel with standard care; the output is not a primary diagnosis.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a retrospective, blinded, multicenter, multinational study in 814 non-contrast head CT (ICH) and 476 head CTA (LVO) cases from 3 clinical sources, with ground truth by concurrence of three US-board-certified neuroradiologist readers. ICH sensitivity was 91.4% (95% CI 87.2%-94.5%) and specificity 97.5% (95% CI 95.8%-98.6%); LVO sensitivity was 97.9% (95% CI 94.6%-99.4%) and specificity 97.6% (95% CI 95.1%-99%). Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
CINA analyzes nonenhanced head CT for suspected intracranial hemorrhage and head CTA for suspected large-vessel occlusion for computer-aided triage and notification in parallel with standard care; the output is not a primary diagnosis.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
CT image networking, processing, enhancement, triage, measurement, or professional workflow support.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported CT or CTA DICOM images and the metadata required by the exact release-specific processing workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Processed CT image objects, measurements, notifications, or worklist outputs for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiology workstations, connected imaging environments, or other exact-release CT-processing workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified radiologists and other trained imaging professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Input protocol, contrast, anatomy, model, software version, output review, and local integration limits are release-specific. CINA analyzes nonenhanced head CT for suspected intracranial hemorrhage and head CTA for suspected large-vessel occlusion for computer-aided triage and notification in parallel with standard care; the output is not a primary diagnosis.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports a retrospective, blinded, multicenter, multinational study in 814 non-contrast head CT (ICH) and 476 head CTA (LVO) cases from 3 clinical sources, with ground truth by concurrence of three US-board-certified neuroradiologist readers. ICH sensitivity was 91.4% (95% CI 87.2%-94.5%) and specificity 97.5% (95% CI 95.8%-98.6%); LVO sensitivity was 97.9% (95% CI 94.6%-99.4%) and specificity 97.6% (95% CI 95.1%-99%). Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Avicenna.AI conducted a retrospective, blinded, multicenter, multinational study with the CINA software with the primary endpoint to evaluate the software’s performance in 1) non-contrast CT" … "(NCCT) head images pertaining to patient with suspected intracranial hemorrhage (ICH) findings and 2) CT angiography (CTA) head series pertaining to patient with suspected large vessel occlusion (LVO) findings, in 814 and 476 clinical anonymized cases, respectively.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports a retrospective, blinded, multicenter, multinational study in 814 non-contrast head CT (ICH) and 476 head CTA (LVO) cases from 3 clinical sources, with ground truth by concurrence of three US-board-certified neuroradiologist readers. ICH sensitivity was 91.4% (95% CI 87.2%-94.5%) and specificity 97.5% (95% CI 95.8%-98.6%); LVO sensitivity was 97.9% (95% CI 94.6%-99.4%) and specificity 97.6% (95% CI 95.1%-99%). Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Avicenna.AI conducted a retrospective, blinded, multicenter, multinational study with the CINA software with the primary endpoint to evaluate the software’s performance in 1) non-contrast CT" … "(NCCT) head images pertaining to patient with suspected intracranial hemorrhage (ICH) findings and 2) CT angiography (CTA) head series pertaining to patient with suspected large vessel occlusion (LVO) findings, in 814 and 476 clinical anonymized cases, respectively.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Standalone sensitivity for ICH on 814 non-contrast head CT cases: 91.4% (95% CI 87.2%-94.5%). Standalone sensitivity for LVO on 476 head CTA cases: 97.9% (95% CI 94.6%-99.4%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "the software’s performance in 1) non-contrast CT (NCCT) head images pertaining to patient with suspected intracranial hemorrhage (ICH) findings and 2) CT angiography (CTA) head series pertaining to patient with suspected large vessel occlusion (LVO) findings, in 814 and 476 clinical anonymized cases" … "Sensitivity and specificity for the “ICH” prioritization and triage application were observed to be 91.4% (95% CI: 87.2% – 94.5%) and 97.5% (95% CI: 95.8% – 98.6%), respectively.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

Reported specificity
Standalone specificity for ICH on 814 non-contrast head CT cases: 97.5% (95% CI 95.8%-98.6%). Standalone specificity for LVO on 476 head CTA cases: 97.6% (95% CI 95.1%-99%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "the software’s performance in 1) non-contrast CT (NCCT) head images pertaining to patient with suspected intracranial hemorrhage (ICH) findings and 2) CT angiography (CTA) head series pertaining to patient with suspected large vessel occlusion (LVO) findings, in 814 and 476 clinical anonymized cases" … "Sensitivity and specificity for the “ICH” prioritization and triage application were observed to be 91.4% (95% CI: 87.2% – 94.5%) and 97.5% (95% CI: 95.8% – 98.6%), respectively.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FDA submission-specific verification and validation evidence for K200855

  • DesignRegulatory verification, validation, and labeling evidence reviewed for exact FDA submission K200855.
  • PopulationThe labeled population and test materials for exact submission K200855; a general clinical study population is not established here.
  • Scopeexact submission
  • Tested versionCINA (K200855)
  • IndependenceSponsor or vendor study

K200855

FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.

5 unlinked candidate evidence records are retained for source review and excluded from this evidence display.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported CT or CTA DICOM images and the metadata required by the exact release-specific processing workflow.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA decision summary for K200855 - CINA

  2. Routing

    Source context, not route validation: The exact FDA package describes CINA receiving DICOM images, with a platform providing interoperability with CT modalities or other DICOM nodes such as a DICOM router or PACS, and sending notifications on flagged series to the Worklist Application. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "DICOM images are received, recorded and filtered before processing." … "It provides the necessary requirements for interoperability with existing systems in the hospital radiology department such as CT modalities or other DICOM nodes (DICOM router or PACS for example).". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA decision summary for K200855 - CINA

  3. AI processing

    Source context, not route validation: The exact FDA package describes CINA as running on a standard off-the-shelf server/workstation, with a CINA Platform server whose Worklist client application, described as on premise, receives notifications. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "CINA runs on a standard “off the shelf” server/workstation and is made of the following software components:" … "CINA Platform server that includes the Worklist client application in which notifications from the CINA Image Processing applications (ICH and LVO) are received.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA decision summary for K200855 - CINA

  4. Returned objects

    Source context, not route validation: Processed CT image objects, measurements, notifications, or worklist outputs for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA decision summary for K200855 - CINA

  5. Viewer/worklist/report

    Unresolved route: Processed CT image objects, measurements, notifications, or worklist outputs for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA decision summary for K200855 - CINA

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes CINA as running on a standard off-the-shelf server/workstation, with a CINA Platform server whose Worklist client application, described as on premise, receives notifications. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "CINA runs on a standard “off the shelf” server/workstation and is made of the following software components:" … "CINA Platform server that includes the Worklist client application in which notifications from the CINA Image Processing applications (ICH and LVO) are received.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes CINA receiving DICOM images, with a platform providing interoperability with CT modalities or other DICOM nodes such as a DICOM router or PACS, and sending notifications on flagged series to the Worklist Application. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "DICOM images are received, recorded and filtered before processing." … "It provides the necessary requirements for interoperability with existing systems in the hospital radiology department such as CT modalities or other DICOM nodes (DICOM router or PACS for example).". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
Avicenna.AI's cybersecurity page states ISO/IEC 27001 certification by SGS, IEC 81001-5-1, TLS 1.2+ in transit, encryption at rest, role-based access with least privilege, and a HIPAA business associate agreement for US customers. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Training
The 510(k) summary states CINA is a radiological computer aided triage and notification software indicated for use in the analysis of (1) non enhanced head CT images and (2) CT angiographies of the head, and that the device is intended to assist hospital networks and trained radiologists in workflow triage by flagging and communicating suspected positive findings of (1) head CT images for Intracranial Hemorrhage (ICH) and (2) CT angiographies of the head for large vessel occlusion (LVO).
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

Workflow role

CT image networking, processing, enhancement, triage, measurement, or professional workflow support.

exact submission · checked 2026-09-04

This is a submission-anchored intended-use summary, not a local acceptance result.

Input

Supported CT or CTA DICOM images and the metadata required by the exact release-specific processing workflow.

exact submission · checked 2026-09-04

Exact supported inputs and protocol limits must be confirmed from the complete labeling.

Output

Processed CT image objects, measurements, notifications, or worklist outputs for professional review.

exact submission · checked 2026-09-04

Output review, editing, and downstream use remain release- and site-specific.

Vendor family context

Current vendor material is product-family context for K200855 only; exact release, enabled options, deployment, and local interoperability require confirmation.

product family · checked 2026-09-04

Vendor material is not exact-release evidence unless that linkage is separately proven.

Site validation status

Exact local interfaces, deployment topology, security controls, downtime behavior, and support obligations remain unestablished.

exact submission · checked 2026-09-04

Obtain organization-specific implementation evidence before procurement or clinical use.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K200855
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-06-24
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
15Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not applicable - checked 2026-09-04 - Not applicable

    CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

14 sources - 3 history items

Source ledger

  1. FDA decision summary for K200855 - CINA

    U.S. Food and Drug Administration - Published 2020-06-24 - Accessed 2026-09-04

    Scope: regulatoryIdentity, productIdentity, indication, modality, anatomy, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. CINA model card (K200855)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  8. Avicenna CINA family context

    Avicenna.AI - Accessed 2026-09-04

    Scope: productFamilyContext, workflowRole, implementationCapabilities

  9. Prenatal Nicotine Exposure Raises Male Blood Pressure via FTO-Mediated NOX2/ROS Signaling.

    U.S. National Library of Medicine - Accessed 2026-09-04

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  10. Potential antimicrobial cotton fabrics treated with cinnamaldehyde/chitosan-alginate nanocapsules for food packaging purposes.

    U.S. National Library of Medicine - Accessed 2026-09-04

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  11. Early response of the parathyroid gland to withdrawal of a calcimimetic compound in uremic rats.

    U.S. National Library of Medicine - Accessed 2026-09-04

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  12. Central Venous and Abdominal Pressures and the Inferior Vena Cava

    U.S. National Library of Medicine - Accessed 2026-09-04

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  13. CNS Modification of Food Craving by Neurofeedback

    U.S. National Library of Medicine - Accessed 2026-09-04

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  14. Avicenna.AI Cybersecurity and Data Protection

    Avicenna.AI - Accessed 2026-10-25

    Scope: security

Research history

  1. K200855 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K221240

BriefCase

Aidoc Medical, Ltd.

Authorized purpose: BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of nonenhanced head CT images in adults or transitional adolescents aged 18 and older. The device is intended to assist hospital networks and appropriately trained medical specialists in workflow triage by flagging and communication of suspected positive findings of Intracranial hemorrhage (ICH) pathologies. Briefcase uses an artificial intelligence algorithm to analyze images and highlight cases with detected findings on a Stand-Alone Performance desktop application in parallel to the ongoing standard of care image interpretation. The user is presented with notification for cases with suspected findings. Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended to be used as a diagnostic device. The results of BriefCase are intended to be used in conjunction with other patient information and based on their professional judgment, to assist with triage/prioritization of medical images. Notified clinicians are responsible for viewing full images per the standard of care.

Modality
CT/CTA
Anatomy
Brain
Decision
2022-05-17
FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K250685

Methinks NCCT Stroke

Methinks Software S.L.

Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-06-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history